Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma

Claudio Scavelli, Giulia Di Pietro, Teresa Cirulli, Mauro Coluccia, Angela Boccarelli, Teresa Giannini, Giuseppe Mangialardi, Raffaello Bertieri, Addolorata Maria Luce Coluccia, Domenico Ribatti, Franco Dammacco, Angelo Vacca

Research output: Contribution to journalArticle

Abstract

Therapeutic doses of zoledronic acid markedly inhibit in vitro proliferation, chemotaxis, and capillarogenesis of bone marrow endothelial cells of patients with multiple myeloma. Zoledronic acid also induces a sizeable reduction of angiogenesis in the in vivo chorioallantoic membrane assay. These effects are partly sustained by gene and protein inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in an autocrine loop. Mevastatin, a specific inhibitor of the mevalonate pathway, reverts the zoledronic acid antiangiogenic effect, indicating that the drug halts this pathway. Our results provide evidence of a direct antiangiogenic activity of zoledronic acid on multiple myeloma patient-derived endothelial cells due to at least four different mechanisms identified either in vitro or in vivo. Tentatively, we suggest that the zoledronic acid antitumoral activity in multiple myeloma is also sustained by antiangiogenesis, which would partly account for its therapeutic efficacy in multiple myeloma.

Original languageEnglish
Pages (from-to)3256-3262
Number of pages7
JournalMolecular Cancer Therapeutics
Volume6
Issue number12
DOIs
Publication statusPublished - Dec 1 2007

Fingerprint

zoledronic acid
Multiple Myeloma
Endothelial Cells
Phenotype
Chorioallantoic Membrane
Vascular Endothelial Growth Factor Receptor-2
Mevalonic Acid
Chemotaxis
Bone Marrow Cells
Vascular Endothelial Growth Factor A

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Scavelli, C., Di Pietro, G., Cirulli, T., Coluccia, M., Boccarelli, A., Giannini, T., ... Vacca, A. (2007). Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Molecular Cancer Therapeutics, 6(12), 3256-3262. https://doi.org/10.1158/1535-7163.MCT-07-0311

Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. / Scavelli, Claudio; Di Pietro, Giulia; Cirulli, Teresa; Coluccia, Mauro; Boccarelli, Angela; Giannini, Teresa; Mangialardi, Giuseppe; Bertieri, Raffaello; Coluccia, Addolorata Maria Luce; Ribatti, Domenico; Dammacco, Franco; Vacca, Angelo.

In: Molecular Cancer Therapeutics, Vol. 6, No. 12, 01.12.2007, p. 3256-3262.

Research output: Contribution to journalArticle

Scavelli, C, Di Pietro, G, Cirulli, T, Coluccia, M, Boccarelli, A, Giannini, T, Mangialardi, G, Bertieri, R, Coluccia, AML, Ribatti, D, Dammacco, F & Vacca, A 2007, 'Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma', Molecular Cancer Therapeutics, vol. 6, no. 12, pp. 3256-3262. https://doi.org/10.1158/1535-7163.MCT-07-0311
Scavelli, Claudio ; Di Pietro, Giulia ; Cirulli, Teresa ; Coluccia, Mauro ; Boccarelli, Angela ; Giannini, Teresa ; Mangialardi, Giuseppe ; Bertieri, Raffaello ; Coluccia, Addolorata Maria Luce ; Ribatti, Domenico ; Dammacco, Franco ; Vacca, Angelo. / Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 12. pp. 3256-3262.
@article{92f88050c5f34e3884dd48872f03dadd,
title = "Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma",
abstract = "Therapeutic doses of zoledronic acid markedly inhibit in vitro proliferation, chemotaxis, and capillarogenesis of bone marrow endothelial cells of patients with multiple myeloma. Zoledronic acid also induces a sizeable reduction of angiogenesis in the in vivo chorioallantoic membrane assay. These effects are partly sustained by gene and protein inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in an autocrine loop. Mevastatin, a specific inhibitor of the mevalonate pathway, reverts the zoledronic acid antiangiogenic effect, indicating that the drug halts this pathway. Our results provide evidence of a direct antiangiogenic activity of zoledronic acid on multiple myeloma patient-derived endothelial cells due to at least four different mechanisms identified either in vitro or in vivo. Tentatively, we suggest that the zoledronic acid antitumoral activity in multiple myeloma is also sustained by antiangiogenesis, which would partly account for its therapeutic efficacy in multiple myeloma.",
author = "Claudio Scavelli and {Di Pietro}, Giulia and Teresa Cirulli and Mauro Coluccia and Angela Boccarelli and Teresa Giannini and Giuseppe Mangialardi and Raffaello Bertieri and Coluccia, {Addolorata Maria Luce} and Domenico Ribatti and Franco Dammacco and Angelo Vacca",
year = "2007",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-07-0311",
language = "English",
volume = "6",
pages = "3256--3262",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma

AU - Scavelli, Claudio

AU - Di Pietro, Giulia

AU - Cirulli, Teresa

AU - Coluccia, Mauro

AU - Boccarelli, Angela

AU - Giannini, Teresa

AU - Mangialardi, Giuseppe

AU - Bertieri, Raffaello

AU - Coluccia, Addolorata Maria Luce

AU - Ribatti, Domenico

AU - Dammacco, Franco

AU - Vacca, Angelo

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Therapeutic doses of zoledronic acid markedly inhibit in vitro proliferation, chemotaxis, and capillarogenesis of bone marrow endothelial cells of patients with multiple myeloma. Zoledronic acid also induces a sizeable reduction of angiogenesis in the in vivo chorioallantoic membrane assay. These effects are partly sustained by gene and protein inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in an autocrine loop. Mevastatin, a specific inhibitor of the mevalonate pathway, reverts the zoledronic acid antiangiogenic effect, indicating that the drug halts this pathway. Our results provide evidence of a direct antiangiogenic activity of zoledronic acid on multiple myeloma patient-derived endothelial cells due to at least four different mechanisms identified either in vitro or in vivo. Tentatively, we suggest that the zoledronic acid antitumoral activity in multiple myeloma is also sustained by antiangiogenesis, which would partly account for its therapeutic efficacy in multiple myeloma.

AB - Therapeutic doses of zoledronic acid markedly inhibit in vitro proliferation, chemotaxis, and capillarogenesis of bone marrow endothelial cells of patients with multiple myeloma. Zoledronic acid also induces a sizeable reduction of angiogenesis in the in vivo chorioallantoic membrane assay. These effects are partly sustained by gene and protein inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in an autocrine loop. Mevastatin, a specific inhibitor of the mevalonate pathway, reverts the zoledronic acid antiangiogenic effect, indicating that the drug halts this pathway. Our results provide evidence of a direct antiangiogenic activity of zoledronic acid on multiple myeloma patient-derived endothelial cells due to at least four different mechanisms identified either in vitro or in vivo. Tentatively, we suggest that the zoledronic acid antitumoral activity in multiple myeloma is also sustained by antiangiogenesis, which would partly account for its therapeutic efficacy in multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=37549004818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549004818&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-0311

DO - 10.1158/1535-7163.MCT-07-0311

M3 - Article

C2 - 18089719

AN - SCOPUS:37549004818

VL - 6

SP - 3256

EP - 3262

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -